Literature DB >> 7887016

Congenital toxoplasmosis in the Balb/c mouse: prevention of vertical disease transmission and fetal death by vaccination.

C W Roberts1, J M Brewer, J Alexander.   

Abstract

Vertical disease transmission only occurs in Balb/c mice infected with Toxoplasma gondii for the first time during pregnancy. This is similar to the situation in humans, where a previous infection with T. gondii tends to give life-long immunity against reinfection and fetal disease transmission. The Balb/c mouse therefore provides a suitable model to study the effectiveness of T. gondii vaccine candidates. A soluble tachyzoite antigen (STAg) preparation was used to vaccinate female Balb/c mice. STAg was inoculated subcutaneously into Balb/c mice in phosphate-buffered saline (PBS), emulsified in Freund's complete adjuvant (FCA), or entrapped within non-ionic surfactant vesicles (NISV). While all inocula induced cellular immunity as measured by parasite-specific spleen cell proliferation in vitro, the highest mean proliferative values were observed in spleens from mice where NISV had been used as the adjuvant and the lowest values were observed where FCA had been used. More importantly, cultures from the NISV/STAg vaccinated mice produced significantly more gamma-interferon than the other experimental groups. This vaccine formulation was therefore identified as that most likely to induce protective immunity against toxoplasmosis. Mice were inoculated subcutaneously with either NISV/STAg or STAg in PBS 4 and 2 weeks before mating and infected orally with 20 tissue cysts of T. gondii on day 12 of pregnancy. The incidence of fetal infection and death in these mice and non-vaccinated infected dams was compared. Of 84 pups born to 14 non-vaccinated dams 45 were viable, of which 18 were found to be infected on reaching maturity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7887016     DOI: 10.1016/0264-410x(94)90147-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene.

Authors:  H V Nielsen; S L Lauemøller; L Christiansen; S Buus; A Fomsgaard; E Petersen
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Immunization of BALB/c mice with killed Neospora caninum tachyzoite antigen induces a type 2 immune response and exacerbates encephalitis and neurological disease.

Authors:  T V Baszler; T F McElwain; B A Mathison
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

3.  Different roles for interleukin-4 during the course of Toxoplasma gondii infection.

Authors:  C W Roberts; D J Ferguson; H Jebbari; A Satoskar; H Bluethmann; J Alexander
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

4.  Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB/c mice but not in CBA/J mice.

Authors:  Valerie Letscher-Bru; Alexander W Pfaff; Ahmed Abou-Bacar; Denis Filisetti; Elisabeth Antoni; Odile Villard; Jean-Paul Klein; Ermanno Candolfi
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

5.  Perinatal Listeria monocytogenes susceptibility despite preconceptual priming and maintenance of pathogen-specific CD8(+) T cells during pregnancy.

Authors:  Dayna R Clark; Vandana Chaturvedi; Jeremy M Kinder; Tony T Jiang; Lijun Xin; James M Ertelt; Sing Sing Way
Journal:  Cell Mol Immunol       Date:  2014-09-22       Impact factor: 11.530

6.  Sex-determined resistance to Toxoplasma gondii is associated with temporal differences in cytokine production.

Authors:  C W Roberts; S M Cruickshank; J Alexander
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

Review 7.  Vaccines in Congenital Toxoplasmosis: Advances and Perspectives.

Authors:  Mariana Barros; Daniela Teixeira; Manuel Vilanova; Alexandra Correia; Natercia Teixeira; Margarida Borges
Journal:  Front Immunol       Date:  2021-02-15       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.